ERCC1表达与晚期NSCLC吸烟患者预后的相关性研究

目的 探讨切除修复交叉互补基因1(ERCC1)在晚期非小细胞肺癌(NSCLC)吸烟患者中的表达及其与临床特征与预后的关系.方法 应用PCR技术检测96例晚期NSCLC吸烟患者肿瘤组织中ERCC1的表达水平,分析其表达水平与晚期NSCLC患者临床病理因素、治疗效果及生存期的相关性.结果 ERCC1的表达与吸烟指数有关(P=0.029),与其他临床病理因素无关.ERCC1低表达的患者化疗有效率、中位生存期均优于高表达的患者,差异有统计学意义(P=0.001,P<0.01).结论 ERCC1的表达与吸烟指数有关且ERCC1低表达的患者化疗有效率和中位生存期均优于高表达的患者,提示检测ERCC1对晚期NSCLC吸烟患者的治疗效果及预后的评估有一定参考价值.

Relationship between expression of ERCC1 and prognosis of smoking patients with advanced NSCLC

Objective To investigate the expression of ERCC1 in smoking patients with advanced non-small cell lung cancer(NSCLC) and its relationship with clinical features and prognosis.Methods The expression of ERCC1 was detected in 96 patients with advanced NSCLC by PCR assay.The clinicopathologic factors, treatment effect and survival time were observed.Results The expression of ERCC1 was related to smoking index(P=0.029), but it was not related to other clinicopathological factors.The patients with low expression of ERCC1 had better response rate and median survival time when compared to those with high expression patients.The difference was statistically significant(P=0.001,P<0.01).Conclusion ERCC1 expression is associated with smoking index and the patients with low expression of ERCC1 shows higher chemotherapy efficiency and longer median survival than patients with high expression, which indicates that detection of ERCC1 may be a useful parameter in evaluating the therapeutic effect and prognosis of smoking patients with advanced NSCLC.